SYNERGY™ Continues to Lead in Complex Patients

SYNERGY BP-DES was intentionally designed with a fast-absorbing polymer for early healing. The latest clinical evidence from the SENIOR Trial and EVOLVE Short DAPT Trial demonstrated excellent results with the SYNERGY BP-DES. EVOLVE Short DAPT reported 3-month data in high bleeding-risk patients and reported extremely favorable ischemic outcomes through 3 months: Cardiac Death: 1.2% MI: 1.4%; TLR 0.3%; Definite/probable ST: 0.3%.

In addition, 2-year data from the SENIOR Trial was reported and continued to provide meaningful evidence on under-represented senior patient population. Key highlights include:

  • Extremely low def/prob ST following discontinuation of 1-month DAPT (0.6% w/ SYNERGY vs. 1.4% w/ BMS)
  • Statistically significant results in ID-TLR following discontinuation of 1-month DAPT at 2-years (1.7% w/ SYNERGY vs 8% w/ BMS)
  • No compromise to other efficacy or BARC endpoints

Leading the Fight Against Calcium

Boston Scientific is driving meaningful innovation in the treatment of complex patients, as witnessed during hands-on training with the newly-approved ROTAPRO and the release of compelling new data.

From hands-on training within the Interactive Training Pavilion and extensive usage during live cases to the release of the PREPARE-CALC trial results, which showed rotational atherectomy and was safe and effective for vessel preparation in severe calcium, the message is clear: Boston Scientific offers the breadth and depth needed to help you master the complex.

Contact your sales representative today to learn more about Boston Scientific’s advancements in calcium management and vessel prep.  


Class Effect Among Non-Hyperemic Pressure Ratios (NHPR)

Do all roads lead to Rome when it comes to non-hyperemic pressure ratios (NHPR)? Drs. Morton Kern from UC Irvine, Nils Johnson from UT Houston, & Ziad Ali from Columbia University, discuss data presented at TCT 2018 on new options in coronary physiology, such as DFR, and which tool to use when - and why.

Will New HD IVUS Drive Imaging Utilization?

Dr. David Lee from Stanford University, together with Drs. Akiko Maehara and Ziad Ali from Columbia University, discuss the value of new Opticross HD 60 MHz IVUS – from ease of image interpretation and no contrast PCI, to detection of fine structures not visible with 40 MHz IVUS.  

LOTUS™ Valve Data Highlights

Results from the two-year REPRISE III data, the first head-to-head TAVR IDE trial comparing the LOTUS valve to the Evolut R/CoreValve, showed that LOTUS valve patients experienced fewer disabling strokes, fewer repeat procedures, more improvements in NYHA class, and continued best-in-class PVL rates with 86.4% none/trace.

Five-year outcomes from REPRISE II, a prospective, multi-center trial of 120 patients treated with the LOTUS valve, demonstrated good hemodynamic results, minimal paravalvular leak, and durable improvement in NYHA classification, with a favorable safety profile.

In an analysis of PVL and 2-year outcomes in the RESPOND study, significant predictors of mild or greater PVL at discharge included a history of cerebrovascular accidents and history of renal failure. All-cause mortality, cardiovascular mortality, and hospitalization were numerically higher in patients with PVL as well.  


EWOLUTION Two-Year data on Single Antiplatelet/No Therapy Subgroup Analysis

Following the conclusion of the EWOLUTION registry and patients’ completion of 2-years of follow up, insights on real-world WATCHMAN patients were unveiled by Dr. Martin Bergmann. Dr. Bergmann, whose sub-analysis evaluated patients after having switched to aspirin, observed that these patients not only showed the same stroke risk reduction as the broader cohort but also showed an impressive bleed reduction of 73% - suggesting the protection comes from WATCHMAN, not from the short course of OAC/DAPT

This reduction in bleeding is consistent with the reduction in bleeding seen in the PROTECT AF and PREVAIL meta analysis demonstrating a 72% relative reduction after the short course of concomitant medications

Contact your sales representative today to learn more about Boston Scientific’s advancements in left atrial appendage therapy.  


ELUVIA™ Demonstrates Superiority in the First Head-to-Head DES SFA Trial

Hear the full IMPERIAL Trial presentation from the Principal Investigator, William Gray, MD. In IMPERIAL, Eluvia demonstrated 88.5% Primary Patency (Kaplan-Meier) compared to 79.5% for Zilver PTX, which was Statistically Significant (p=0.0119).